Paper40409258
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.
Sirenko M and 34 others. Cell Stem Cell, 2025. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia. Papers, record 40409258. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40409258
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Isocitrate Dehydrogenase | Major topic |
| Mutation | Major topic |
| Humans | |
| Nucleophosmin | |
| Clone Cells | |
| Animals |
Source PubMed
Grants23
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA284595 | NCI NIH HHS | United States | R01CA284595 | PubMed and NIH | NIH RePORTER |
| K08 CA241371 | NCI NIH HHS | United States | K08CA241371 | PubMed and NIH | NIH RePORTER |
| R01 HL128239 | NHLBI NIH HHS | United States | R01HL128239 | PubMed and NIH | NIH RePORTER |
| R01 CA266212 | NCI NIH HHS | United States | R01CA266212 | PubMed | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed | NIH RePORTER |
| R01 HL157387 | NHLBI NIH HHS | United States | R01HL157387 | PubMed and NIH | NIH RePORTER |
| R01 HL159175 | NHLBI NIH HHS | United States | R01HL159175 | PubMed and NIH | NIH RePORTER |
| R01 CA271418 | NCI NIH HHS | United States | R01CA271418 | PubMed and NIH | NIH RePORTER |
| P30 CA016058 | NCI NIH HHS | United States | P30CA016058 | PubMed | NIH RePORTER |
| T32 GM007739 | NIGMS NIH HHS | United States | T32GM007739 | PubMed and NIH | NIH RePORTER |
| F31 CA254130 | NCI NIH HHS | United States | F31CA254130 | PubMed and NIH | NIH RePORTER |
| P01 CA229086 | NCI NIH HHS | United States | P01CA229086 | PubMed | NIH RePORTER |
| R01 CA298153 | NCI NIH HHS | United States | R01CA298153 | PubMed | NIH RePORTER |
| R01 CA228135 | NCI NIH HHS | United States | R01CA228135 | PubMed and NIH | NIH RePORTER |
| R01 CA283574 | NCI NIH HHS | United States | R01CA283574 | PubMed and NIH | NIH RePORTER |
| P50 CA254838 | NCI NIH HHS | United States | P50CA254838 | PubMed and NIH | NIH RePORTER |
| R01 CA260711 | NCI NIH HHS | United States | R01CA260711 | PubMed and NIH | NIH RePORTER |
| R01 LM013879 | NLM NIH HHS | United States | R01LM013879 | PubMed and NIH | NIH RePORTER |
| R01 CA242020 | NCI NIH HHS | United States | R01CA242020 | PubMed and NIH | NIH RePORTER |
| U54 DK126108 | NIDDK NIH HHS | United States | U54DK126108 | PubMed | NIH RePORTER |
References93
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34427990 | Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. | Cancer Med | 2021 | https://conductscience.org/library/papers/34427990 | PubMed |
| 2 | 27903985 | The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. | Oncotarget | 2017 | https://conductscience.org/library/papers/27903985 | PubMed |
| 3 | 35273342 | In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. | Leukemia | 2022 | https://conductscience.org/library/papers/35273342 | PubMed |
| 4 | 24442143 | The ID proteins: master regulators of cancer stem cells and tumour aggressiveness. | Nat Rev Cancer | 2014 | https://conductscience.org/library/papers/24442143 | PubMed |
| 5 | 25426837 | Age-related clonal hematopoiesis associated with adverse outcomes. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25426837 | PubMed |
| 6 | 31004019 | Clonal hematopoiesis and risk of acute myeloid leukemia. | Haematologica | 2019 | https://conductscience.org/library/papers/31004019 | PubMed |
| 7 | 29898899 | Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. | Genome Res | 2018 | https://conductscience.org/library/papers/29898899 | PubMed |
| 8 | 31597962 | Decoding human fetal liver haematopoiesis. | Nature | 2019 | https://conductscience.org/library/papers/31597962 | PubMed |
| 9 | 31841594 | Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. | Blood | 2020 | https://conductscience.org/library/papers/31841594 | PubMed |
| 10 | 31270458 | Somatic mutations and cell identity linked by Genotyping of Transcriptomes. | Nature | 2019 | https://conductscience.org/library/papers/31270458 | PubMed |
| 11 | 35924979 | The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. | Cancer Discov | 2022 | https://conductscience.org/library/papers/35924979 | PubMed |
| 12 | 28280273 | A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. | Leukemia | 2017 | https://conductscience.org/library/papers/28280273 | PubMed |
| 13 | 28803919 | Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. | Cell Stem Cell | 2017 | https://conductscience.org/library/papers/28803919 | PubMed |
| 14 | 31160568 | A comprehensive single cell transcriptional landscape of human hematopoietic progenitors. | Nat Commun | 2019 | https://conductscience.org/library/papers/31160568 | PubMed |
| 15 | 37098346 | Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia. | Cell Stem Cell | 2023 | https://conductscience.org/library/papers/37098346 | PubMed |
| 16 | 30540953 | The Molecular Signature of Megakaryocyte-Erythroid Progenitors Reveals a Role for the Cell Cycle in Fate Specification. | Cell Rep | 2018 | https://conductscience.org/library/papers/30540953 | PubMed |
| 17 | 39478230 | RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. | Nature | 2024 | https://conductscience.org/library/papers/39478230 | PubMed |
| 18 | 24440599 | Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. | Cell Stem Cell | 2014 | https://conductscience.org/library/papers/24440599 | PubMed |
| 19 | 32380538 | Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. | Blood Adv | 2020 | https://conductscience.org/library/papers/32380538 | PubMed |
| 20 | 29262330 | Hepatic Leukemia Factor Maintains Quiescence of Hematopoietic Stem Cells and Protects the Stem Cell Pool during Regeneration. | Cell Rep | 2017 | https://conductscience.org/library/papers/29262330 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42814135 | Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia. | Blood Cancer Discov | 2026 | https://conductscience.org/library/papers/42814135 | PubMed |
| 42745000 | Type 1 interferon perturbates clonal competition by reshaping human blood development. | Nat Genet | 2026 | https://conductscience.org/library/papers/42745000 | PubMed |
| 42711452 | A single-cell lens into the co-evolution of genotypes and phenotypes in cancer. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/42711452 | PubMed |
| 42697881 | Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity. | Nat Commun | 2026 | https://conductscience.org/library/papers/42697881 | PubMed |
| 42642621 | Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome. | Leukemia | 2026 | https://conductscience.org/library/papers/42642621 | PubMed |
| 42402603 | TCA-controlled histone succinylation identifies IDH3B as a prognostic and therapeutic target in AML. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/42402603 | PubMed |
| 42380141 | Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42380141 | PubMed |
| 42367953 | Accurate detection of tumor clonality and ongoing expansion mode from genomic data. | bioRxiv | 2026 | https://conductscience.org/library/papers/42367953 | PubMed |
| 42101375 | Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML. | Blood Adv | 2026 | https://conductscience.org/library/papers/42101375 | PubMed |
| 42073528 | The Spectrum of Venetoclax-Based Treatments in Acute Myeloid Leukemia. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42073528 | PubMed |
| 42007444 | APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications. | Hemasphere | 2026 | https://conductscience.org/library/papers/42007444 | PubMed |
| 41936394 | Rare Gain-of-Function Variants in IDH1 and IDH2 Confer Increased Risk of Immune-Mediated Rheumatic Diseases. | ACR Open Rheumatol | 2026 | https://conductscience.org/library/papers/41936394 | PubMed |
| 41860384 | IDH1- and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation. | Blood Adv | 2026 | https://conductscience.org/library/papers/41860384 | PubMed |
| 41814014 | Immunophenotypic changes following menin inhibition in acute myeloid leukemia. | Leukemia | 2026 | https://conductscience.org/library/papers/41814014 | PubMed |
| 41703030 | Reframing-renaming(?)-myelodysplastic syndromes/neoplasms and clonal hematopoiesis of indeterminate potential. | Leukemia | 2026 | https://conductscience.org/library/papers/41703030 | PubMed |
| 41460204 | MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41460204 | PubMed |
| 41258574 | Epigenetic reprogramming as the nexus of cancer stemness and therapy resistance: implications for biomarker discovery. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41258574 | PubMed |
| 41046303 | Elucidating the risk factors and oncogene drivers of acute myeloid leukemia. | Hum Cell | 2025 | https://conductscience.org/library/papers/41046303 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HLA-C | 3107 | PubTator's text mining | https://conductscience.org/library/genes/3107 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| IDH2 | 3418 | PubTator's text mining | https://conductscience.org/library/genes/3418 | NCBI Gene |
| NPM1 | 4869 | PubTator's text mining | https://conductscience.org/library/genes/4869 | NCBI Gene |
| NRAS | 4893 | PubTator's text mining | https://conductscience.org/library/genes/4893 | NCBI Gene |
| SRSF2 | 6427 | PubTator's text mining | https://conductscience.org/library/genes/6427 | NCBI Gene |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| GEO | GSE230559 |
Source GEO
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40409258
GET https://conductscience.org/api/papers/v1/40409258/authors?page=2